CSHP - California Society of Health-System Pharmacists

Advance Your Practice: Understanding Current Standards of Care for Thyroid Dysfunction 🩺💡

Looking to sharpen your clinical knowledge on managing thyroid disorders? Join CSHP’s affiliate chapter, the Inland Society of Health-System Pharmacists (ISHP), for an upcoming knowledge-based webinar designed for both pharmacists and pharmacy technicians.

We are excited to feature Megan Ly, PharmD, a PGY-1 Pharmacy Resident at the VA Loma Linda Healthcare System, as she breaks down the essential clinical guidelines and evidence-based treatments you need to know.

Don't miss out on this valuable continuing education opportunity! Secure your virtual seat today.

Register at: https://www.cshp.org/CSHP_Webinar6-15-2026

BIG NEWS! AB 2571 is moving forward! 🚀💊

Thanks to our collective voice, Assembly Bill 2571 has officially cleared the Senate Health Committee! This is a huge win for patient safety and the pharmacy profession in California—but our work isn’t done yet.

Next stop: The Senate Appropriations Committee. 🏛️

We need EVERY CSHP member, student, and tech to help us maintain this momentum. Lawmakers need to hear directly from YOU, the frontline practitioners, about why this legislation is critical for our patients and our practice.

How you can help:
1️⃣ Click the link in our bio.
2️⃣ Submit your grassroots letter of support (it takes

FDA Approves Drug to Treat Relapsed or Refractory Mantle Cell Lymphoma

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to a treatment for adults with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor. Sonrotoclax (Beqalzi) is a B-cell lymphoma 2 (BCL-2) inhibitor administered as an oral tablet.

The safety and efficacy of sonrotoclax (Beqalzi) were evaluated in a single-arm, multicenter trial in 103 adults with relapsed or refractory MCL who previously received anti-CD20-based therapy and a BTK inhibitor. Efficacy was established based on overall response rate (ORR) and duration of response (DOR), as assessed by an independent review committee (IRC) using Lugano criteria.

Warning and precautions for sonrotoclax (Beqalzi) include tumor lysis syndrome (TLS), serious infections, and neutropenia. The most common adverse reactions for sonrotoclax (Beqalzi) reported most frequently among the 115 patients with MCL were pneumonia (10%).

View the FDA’s announcement here:
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sonrotoclax-relapsed-or-refractory-mantle-cell-lymphoma

Ready to take the stage? 🎙️ The PCPSC 2027 Call for Speakers is officially open!

CSHP and the Chapman University School of Pharmacy are looking for dynamic speakers to present at the Pacific Coast Patient Safety Conference next March in Coronado, CA! 🌊✨

If you are passionate about advancing patient outcomes, implementing cutting-edge safety protocols, or sharing critical clinical insights with healthcare professionals across the coast, we want your voice in the lineup.

📌 Important Dates:
• Proposal Deadline: August 7, 2026
• Conference: March 4-5, 2027

Apply today at ➡️ https://www.cshp.org/PCPSC_CFS_2027

Dedicated to Care, Driven by Purpose. Meet Hannah Manio! 🌟💊

Huge congratulations to Hannah Manio for being named the OCSHP Student of the Year! 🏆

Hannah’s journey from a family of caregivers to a standout leader at UC Irvine is a powerful reminder of how much of an impact student pharmacists can make. Whether she's designing engaging summer health workshops for local kids at the Boys & Girls Club, presenting clinical research, or educating legislators on the essential role of pharmacists, Hannah always leads with heart.

Read our latest Member Spotlight and see how Hannah is changing perspectives on what pharmacists can achieve in our communities 👉 https://bit.ly/4uk0RwO

FDA Approves Drug to Treat NRG1 Fusion-Positive Cholangiocarcinoma

The U.S. Food and Drug Administration (FDA) has approved a treatment for adults with advanced, unresectable, or metastatic cholangiocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy. Zenocutuzumab-zbco (Bizengri) is a bispecific HER2- and HER3-directed antibody administered as an intravenous injection.

The safety and efficacy of zenocutuzumab-zbco (Bizengri) were evaluated in a multicenter, open-label, multi-cohort clinical trial of 22 adults with advanced solid tumors. A total of 22 patients with unresectable or metastatic NRG1 fusion-positive cholangiocarcinoma were enrolled in the eNRGy trial, with 19 evaluable for efficacy. The major efficacy outcome measures were confirmed overall response rate (ORR) and duration of response (DOR) as determined by a blinded independent central review according to RECIST v1.1.

Warning and precautions for zenocutuzumab-zbco (Bizengri) include infusion-related reactions, hypersensitivity, anaphylactic reactions, interstitial lung disease (ILD), pneumonitis, left ventricular dysfunction, and embryo-fetal toxicity. The most common adverse reactions for zenocutuzumab-zbco (Bizengri) include diarrhea, musculoskeletal pain, fatigue, nausea, infusion-related reactions (IRR), dyspnea, rash, constipation, vomiting, abdominal pain, and edema.

View the FDA’s announcement here:
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-zenocutuzumab-zbco-advanced-unresectable-or-metastatic-cholangiocarcinoma

Got research? 🧠 Put your work in the spotlight at Seminar 2026! 🏰💊

The clock is ticking! The deadline to submit your poster abstract for Seminar 2026 is officially July 17, 2026.

Presenting a poster is one of the best ways to advance your pharmacy career, build your professional network, and share your unique clinical insights with peers from all over California. From innovative operational projects to cutting-edge clinical cases, your work deserves a stage!

Join us at the iconic Disneyland® Hotel this November 5-8th. Scan the QR code on click the link below for details: https://www.cshp.org/S26_Posters

CDPH Releases Warning of Rising Illnesses from Ongoing Unseasonal Bloom of Poisonous Wild Mushrooms

The California Department of Public Health (CDPH) issued a communication regarding a resurgence of poisoning cases linked to accidental picking and consumption of poisonous wild mushrooms in the state of California. Death Caps and Western Destroying Angels are types of poisonous wild mushrooms that grow in many regions across the state. Death Caps and Western Destroying Angels closely resemble several edible mushroom species in both appearance and taste, which makes it difficult to distinguish them from safe varieties.

The CDPH strongly recommends that all Californians not pick or eat wild mushrooms. The risk of potentially ingesting deadly amatoxin poisoning remains extremely high. The outbreak has been ongoing for several months and continues to cause severe liver damage in both children and adults. Four deaths and four liver transplants related to amatoxin poisoning have occurred among the 50 identified cases.

The CDPH recommends healthcare providers refer to the CDPH California Health Advisory Update related on May 14, 2026.

View the CDPH announcement here:
https://www.cdph.ca.gov/Programs/OPA/Pages/NR26-023.aspx

View the CDPH HAN Update here:
https://www.cdph.ca.gov/Programs/OPA/Pages/CAHAN/Outbreak-of-Severe-Illness-and-Deaths-Linked-to-Ingestion-of-Poisonous-Wild-Mushrooms-%E2%80%93-May-2026-Update.aspx

FDA Approves Drug to Treat Breast Cancer with Disease Progression

The U.S. Food and Drug Administration (FDA) has approved a treatment for adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy. Vepdegestrant (Veppanu) is a heterobifunctional protein degrader administered as an oral tablet. The FDA approved the Guardant360 CDx as a companion diagnostic device to identify patients with breast cancer with ESR1 mutations for treatment with vepdegestrant (Veppanu).

The safety and efficacy of vepdegestrant (Veppanu) were evaluated in a randomized, open-label, active-controlled, multicenter trial in 624 adults with ER-positive, HER2-negative, advanced or metastatic breast cancer, of whom 270 had tumors carrying ESR1 mutations. The major efficacy outcome measure was progression-free survival (PFS) as assessed by blinded independent central review (BICR) in the population of patients whose tumors had an ESR1 mutation and in the overall population.

Warning and precautions for vepdegestrant (Veppanu) include QTc interval prolongation and embryo-fetal toxicity. The most common (≥10%) adverse reactions for vepdegestrant (Veppanu) include laboratory abnormalities, decreased white blood cells, increased AST, musculoskeletal pain, fatigue, decreased hemoglobin, decreased neutrophils, increased ALT, increased alkaline phosphatase, nausea, decreased blood potassium, increased bilirubin, decreased appetite, electrocardiogram QT prolonged, decreased platelets, and constipation.

View the FDA’s announcement here:
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-vepdegestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast

Stronger Together! Adventist Health Backs AB 2571 ✨🏥

We have some incredible advocacy news to share! Adventist Health has officially joined our growing coalition by submitting a Letter of Support for AB 2571!

What does this mean for Californians? It means a major healthcare system is standing with us to eliminate the barriers that prevent patients from receiving critical medication management services directly within their local care settings. AB 2571 ensures that highly trained advanced practice pharmacists can fully utilize their skills to protect patient safety and deliver optimal care—regardless of the clinical setting.

The Senate Health Committee reviews this vital bill in early June, and the momentum is undeniable!

✨ Read the full letter from Adventist Health at: https://www.cshp.org/AB2571